NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Neuphoria Therapeutics Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026
$3.31+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $17.90M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.21 (−78.67%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Neuphoria Therapeutics Inc. saw revenue fall 92.5% to $1.17M over fiscal 2026.
Revenue
$1.17M
-92.5% vs. a year earlier
Operating income
-$16.45M
TTM Q4 2026
EPS, diluted
-$3.06
FY2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $17.90M
- P/E ratio
- –
- Price to sales
- 15.24
- Price to book
- 0.73
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.17M
- Net income
- -$13.45M
- EPS, diluted
- -$3.06
- Book value per share
- $4.55
- Diluted shares
- 5M
Seven years at a glance
Fiscal years 2020 to 2026, USD
Revenue
$1.17M-92.5% YoY
Operating income
-$16.45M
Net income
-$13.45M
EPS, diluted
-$3.06
Reported period